Data, narratives and tools produced by the Kits' sector/GeneDxChart: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 413: | Line 413: | ||
| | | | ||
|[3] | |[3] | ||
|http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm? | |http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?{| | | ||
|Type | |||
|disease / drug tested | |||
|genes | |||
|patent holder and/or exclusive licensees | |||
|Companies | |||
|Number of US labs offering testing | |||
|license | |||
|key patents | |||
|other patents | |||
|product | |||
|typical testing cost | |||
|notes | |||
|report | |||
|links | |||
|References | |||
| | |||
| | |||
| | | | ||
| | | | ||
|---- | |||
|Dx | |||
|Breast & Ovarian Cancer | |||
|BRCA1 | |||
|Myriad Genetics | |||
|Myriad Genetics | |||
|1 | |||
|exclusive | |||
|5753441, 6051379, | |||
| | | | ||
|BRACAnalysis | |||
|$3120 [2] | |||
| | |||
|[1], [2] | |||
|http://www.myriad.com/products/bracanalysis.php | |||
|[1] Cook-Deegan et al. The dangers of diagnostic monopolies. Nature (2009) vol. 458 (7237) pp. 405-6 | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|---- | |||
| | | | ||
| | | | ||
|BRCA2 | |||
| | | | ||
| | | | ||
Line 435: | Line 468: | ||
| | | | ||
| | | | ||
|[2] SACGHS. Appendix 1: Compendium of Case Studies on the Impact of Gene Patents and Licensing Practices on Access to Genetic Testing. (2009) pp. 1-305 | |||
| | | | ||
| | | | ||
Line 440: | Line 474: | ||
| | | | ||
|---- | |---- | ||
|Dx | |||
|colorectal cancer (HNPCC) | |||
|MLH1 | |||
|Oregon Health Sciences University + Dana Farber; Johns Hopkins | |||
|Baylor, Boston University, City of Hope, Harvard, Huntington, Mayo Clinic, University of Pennsylvania, Quest, Myriad, | |||
|? | |||
|? | |||
|5922855, 5591826 (protein), 5693470 | |||
| | |||
|? | |||
|Myriad, MLH1 + MSH2 + MSH6: $2950; see [2] pg A-12 for more prices | |||
| Cho M et al. Effect of patents and licenses on the provision of clinical genetic testing services. Journal of Molecular Diagnostics 2003 (February). 5(1):3-8. NB: FAP and HNPCC “patent enforcements” are more unlikely given non-exclusive licensing and multiple rights-holders. | |||
|[1], [2] | |||
| | | | ||
|[3] Flockhart et al. Clinically available pharmacogenomics tests. Clinical pharmacology and therapeutics (2009) vol. 86 (1) pp. 109-13 | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|---- | |||
| | | | ||
| | | | ||
|MSH2 | |||
| | | | ||
| | | | ||
Line 459: | Line 509: | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|---- | |||
| | | | ||
| | | | ||
|MSH6 | |||
| | | | ||
| | | | ||
Line 479: | Line 530: | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|---- | |||
|Dx | |||
|colorectal cancer (FAP) | |||
|APC | |||
| | | | ||
| | | | ||
Line 501: | Line 555: | ||
|---- | |---- | ||
| | | | ||
| | |||
|MYH | |||
| | | | ||
| | | | ||
Line 517: | Line 573: | ||
| | | | ||
| | | | ||
|---- | |||
|Dx | |||
|Alzheimer’s, late-onset (LOAD, AD2) | |||
|APOE | |||
|Duke university -> Athena Diagnostics (2 method patents for Dx alzheimer’s, don’t claim sequence, Bilski could destabilize; one claiming a kit) see [2]p B-6 | |||
|Athena (St Louis Health Science Center offers cheaper APOE Dx for cardivascular disease; SunnyBrook Molecular Genetics Laboratory & McGill University Health Center provide APOE testing for AD for ~$100 canadian, [2]B-8) | |||
|1 | |||
|exclusive | |||
|5508167, 5716828, 6027896 | |||
| | |||
|ADmark® ApoE Genotype Analysis & Interpretation (Symptomatic) | |||
|$475 ($365 for cardiovascular sequencing by St Louis Health Science Center, see note) | |||
|Cook-Deegan notes “penumbra effect” wrt Athena. Athena sublicensed APOE for DTC testing to Smart Genetics, but First Inventor on patent raised licensing complaints for ethical reasons ([2] B-16). APOE also is a marker for cardiovascular disease; testing for which does not infringe the methods patents, see [2]B-8; http://snpedia.com/index.php/Alzheimer's_disease. Also 2 testing labs in Canada, McGill and Sunnybrook both offer APOE testing for AD for $100 & $120 respectively [2]B-8. | |||
| | | | ||
|http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/qid/35 | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|---- | |||
| | | | ||
|Alzheimer’s, early-onset (EOAD, AD3) | |||
|PSEN1 | |||
|Hospital for Sick Children, U Toronto -> Athena | |||
|Athena | |||
|1 | |||
|exclusive | |||
|6194153 | |||
|5986054, 6531586, 6248555(dropped), | |||
|ADmark® PS-1 DNA Sequencing Test | |||
|$1675 ([2]B-15) | |||
| | | | ||
| | | | ||
|http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/q/id/1261 | |||
| | | | ||
| | | | ||
Line 532: | Line 613: | ||
| | | | ||
| | | | ||
|---- | |||
| | | | ||
|Alzheimer’s, early-onset (EOAD, AD4) | |||
|PSEN2 | |||
|Hospital for Sick Children -> Athena | |||
|Athena | |||
|1 | |||
|exclusive | |||
|5840540 | |||
|6485911 | |||
|ADmark® PS-2 DNA Sequencing Test | |||
|$1500?* | |||
|* http://www.alz.org/co/documents/2009_Symposium_handout_genetics.pdf | |||
| | | | ||
|http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/q/id/1259 | |||
| | | | ||
| | | | ||
Line 541: | Line 635: | ||
|---- | |---- | ||
| | | | ||
|Alzheimer’s, early-onset (EOAD, AD1) | |||
|APP | |||
|? | |||
|Athena | |||
|2 | |||
|? | |||
|? | |||
| | |||
|ADmark® APP DNA Sequencing/Duplication Test; SignatureFISH | |||
|$1000?* | |||
|Signature genomics provides a FISH -based test for APP; only Athena does complete sequencing | |||
| | | | ||
|http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/q/id/1260 http://www.signaturegenomics.com/signaturefish.html | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | |||
|---- | |||
|Dx | |||
|Haemochromatosis | |||
|HFE | |||
|Bio-Rad | |||
| | | | ||
| | | | ||
Line 551: | Line 663: | ||
| | | | ||
| | | | ||
|mDx Hereditary Hemochromatosis ASR kit; mDx Hereditary Hemochromatosis LLA ASR | |||
| | | | ||
|Merz JF, Kriss AG, Leonard DGB, Cho MK. Op. cit. Examine licensing activities around HFE and impact on diagnostic prices | |||
| | | | ||
| | | | ||
Line 560: | Line 674: | ||
| | | | ||
|---- | |---- | ||
|Dx | |||
|Cystic Fibrosis | |||
|CFTR | |||
|University of Michigan, Hospital for Sick Children | |||
| | | | ||
|112 | |||
|non-exclusive | |||
|5776677 | |||
|5876974, 7118911, 6984487, 6730777, 5407796 | |||
| | | | ||
| | | | ||
|Johns Hopkins also has some key CFTR patents. | |||
| | | | ||
| | | | ||
Line 570: | Line 693: | ||
| | | | ||
| | | | ||
|---- | |||
|Dx | |||
|Long-QT syndrome | |||
| | | | ||
|PGxHealth; Bio-Reference Laboratories | |||
| | | | ||
| | | | ||
Line 579: | Line 706: | ||
| | | | ||
| | | | ||
| | |[1], [2] | ||
| | | | ||
| | | | ||
Line 586: | Line 713: | ||
| | | | ||
| | | | ||
|---- | |||
|Dx | |||
|Spinocerebellar Ataxia | |||
| | | | ||
|Athena Diagnostics | |||
| | | | ||
| | | | ||
|exclusive | |||
| | | | ||
| | | | ||
| | | | ||
|Cook-Deegan notes “penumbra effect” wrt Athena | |||
| | | | ||
|[1], [2] | |||
| | | | ||
| | | | ||
Line 600: | Line 734: | ||
| | | | ||
|---- | |---- | ||
|Dx | |||
|Tay-Sachs Disease | |||
| | | | ||
| | | | ||
Line 610: | Line 746: | ||
| | | | ||
| | | | ||
|[1], [2] | |||
| | | | ||
| | | | ||
Line 616: | Line 753: | ||
| | | | ||
| | | | ||
|---- | |||
|Dx | |||
|Canavan Disease | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
Line 627: | Line 766: | ||
| | | | ||
| | | | ||
|[1], [2] | |||
| | | | ||
| | | | ||
Line 633: | Line 773: | ||
| | | | ||
| | | | ||
|---- | |||
|PGx | |||
|Coumadin (Warfarin) | |||
|CYP2C9 | |||
| | | | ||
| | | | ||
Line 639: | Line 783: | ||
| | | | ||
| | | | ||
| | |Nanosphere Verigene Warfarin Metabolism Nucleic Acid Test | ||
| | | | ||
| | | | ||
|[3] | |||
|http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108967.htm | |||
| | | | ||
| | | | ||
Line 647: | Line 793: | ||
| | | | ||
| | | | ||
|---- | |||
|PGx | |||
|Coumadin (Warfarin) | |||
|VKORC1 | |||
| | | | ||
| | | | ||
Line 656: | Line 806: | ||
| | | | ||
| | | | ||
|[3] | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|---- | |||
|PGx | |||
|Sprycel (dasatinib) | |||
|BCR-ABL | |||
| | | | ||
| | | | ||
Line 672: | Line 826: | ||
| | | | ||
| | | | ||
|[3] | |||
|http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?|-ype | |||
|disease / drug tested | |||
|genes | |||
|patent holder and/or exclusive licensees | |||
|Companies | |||
|Number of US labs offering testing | |||
|license | |||
|key patents | |||
|other patents | |||
|product | |||
|typical testing cost | |||
|notes | |||
|report | |||
|links | |||
|References | |||
| | | | ||
| | | | ||
|- | |||
|- | |||
|Dx | |||
|Breast & Ovarian Cancer | |||
|BRCA1 | |||
|Myriad Genetics | |||
|Myriad Genetics | |||
|1 | |||
|exclusive | |||
|5753441, 6051379, | |||
| | | | ||
|BRACAnalysis | |||
|$3120 [2] | |||
| | |||
|[1], [2] | |||
|http://www.myriad.com/products/bracanalysis.php | |||
|[1] Cook-Deegan et al. The dangers of diagnostic monopolies. Nature (2009) vol. 458 (7237) pp. 405-6 | |||
| | | | ||
| | | | ||
|- | |||
|- | |||
| | | | ||
| | | | ||
| | |BRCA2 | ||
| | | | ||
| | | | ||
Line 691: | Line 879: | ||
| | | | ||
| | | | ||
|[2] SACGHS. Appendix 1: Compendium of Case Studies on the Impact of Gene Patents and Licensing Practices on Access to Genetic Testing. (2009) pp. 1-305 | |||
| | | | ||
| | | | ||
|- | |||
|- | |||
|Dx | |||
|colorectal cancer (HNPCC) | |||
|MLH1 | |||
|Oregon Health Sciences University + Dana Farber; Johns Hopkins | |||
|Baylor, Boston University, City of Hope, Harvard, Huntington, Mayo Clinic, University of Pennsylvania, Quest, Myriad, | |||
|? | |||
|? | |||
|5922855, 5591826 (protein), 5693470 | |||
| | | | ||
|? | |||
|Myriad, MLH1 + MSH2 + MSH6: $2950; see [2] pg A-12 for more prices | |||
| Cho M et al. Effect of patents and licenses on the provision of clinical genetic testing services. Journal of Molecular Diagnostics 2003 (February). 5(1):3-8. NB: FAP and HNPCC “patent enforcements” are more unlikely given non-exclusive licensing and multiple rights-holders. | |||
|[1], [2] | |||
| | | | ||
|[3] Flockhart et al. Clinically available pharmacogenomics tests. Clinical pharmacology and therapeutics (2009) vol. 86 (1) pp. 109-13 | |||
| | | | ||
| | | | ||
|---- | |||
| | | | ||
| | | | ||
| | |MSH2 | ||
| | | | ||
| | | | ||
Line 714: | Line 919: | ||
| | | | ||
| | | | ||
|---- | |||
| | | | ||
| | | | ||
|MSH6 | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
Line 731: | Line 937: | ||
| | | | ||
| | | | ||
|- | |||
|- | |||
|Dx | |||
|colorectal cancer (FAP) | |||
|APC | |||
| | | | ||
| | | | ||
Line 739: | Line 950: | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
Line 746: | Line 956: | ||
| | | | ||
| | | | ||
|---- | |||
| | | | ||
| | | | ||
|MYH | |||
| | | | ||
| | | | ||
Line 759: | Line 971: | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|- | |||
|- | |||
|Dx | |||
|Alzheimer’s, late-onset (LOAD, AD2) | |||
|APOE | |||
|Duke university -> Athena Diagnostics (2 method patents for Dx alzheimer’s, don’t claim sequence, Bilski could destabilize; one claiming a kit) see [2]p B-6 | |||
|Athena (St Louis Health Science Center offers cheaper APOE Dx for cardivascular disease; SunnyBrook Molecular Genetics Laboratory & McGill University Health Center provide APOE testing for AD for ~$100 canadian, [2]B-8) | |||
|1 | |||
|exclusive | |||
|5508167, 5716828, 6027896 | |||
| | | | ||
|ADmark® ApoE Genotype Analysis & Interpretation (Symptomatic) | |||
|$475 ($365 for cardiovascular sequencing by St Louis Health Science Center, see note) | |||
|Cook-Deegan notes “penumbra effect” wrt Athena. Athena sublicensed APOE for DTC testing to Smart Genetics, but First Inventor on patent raised licensing complaints for ethical reasons ([2] B-16). APOE also is a marker for cardiovascular disease; testing for which does not infringe the methods patents, see [2]B-8; http://snpedia.com/index.php/Alzheimer's_disease. Also 2 testing labs in Canada, McGill and Sunnybrook both offer APOE testing for AD for $100 & $120 respectively [2]B-8. | |||
| | | | ||
|http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/qid/35 | |||
| | | | ||
| | | | ||
| | | | ||
|- | |||
|- | |||
| | | | ||
|Alzheimer’s, early-onset (EOAD, AD3) | |||
|PSEN1 | |||
|Hospital for Sick Children, U Toronto -> Athena | |||
|Athena | |||
|1 | |||
|exclusive | |||
|6194153 | |||
|5986054, 6531586, 6248555(dropped), | |||
|ADmark® PS-1 DNA Sequencing Test | |||
|$1675 ([2]B-15) | |||
| | | | ||
| | | | ||
|http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/q/id/1261 | |||
| | | | ||
| | | | ||
| | | | ||
|- | |||
|- | |||
| | | | ||
|Alzheimer’s, early-onset (EOAD, AD4) | |||
|PSEN2 | |||
|Hospital for Sick Children -> Athena | |||
|Athena | |||
|1 | |||
|exclusive | |||
|5840540 | |||
|6485911 | |||
|ADmark® PS-2 DNA Sequencing Test | |||
|$1500?* | |||
|* http://www.alz.org/co/documents/2009_Symposium_handout_genetics.pdf | |||
| | | | ||
|http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/q/id/1259 | |||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
|- | |||
| | | | ||
|Alzheimer’s, early-onset (EOAD, AD1) | |||
|APP | |||
|? | |||
|Athena | |||
|2 | |||
|? | |||
|? | |||
| | | | ||
|ADmark® APP DNA Sequencing/Duplication Test; SignatureFISH | |||
|$1000?* | |||
|Signature genomics provides a FISH -based test for APP; only Athena does complete sequencing | |||
| | | | ||
|http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/q/id/1260 http://www.signaturegenomics.com/signaturefish.html | |||
| | | | ||
| | | | ||
| | | | ||
|- | |||
|- | |||
|Dx | |||
|Haemochromatosis | |||
|HFE | |||
|Bio-Rad | |||
| | | | ||
| | | | ||
Line 791: | Line 1,061: | ||
| | | | ||
| | | | ||
|mDx Hereditary Hemochromatosis ASR kit; mDx Hereditary Hemochromatosis LLA ASR | |||
| | | | ||
|Merz JF, Kriss AG, Leonard DGB, Cho MK. Op. cit. Examine licensing activities around HFE and impact on diagnostic prices | |||
| | | | ||
| | | | ||
Line 797: | Line 1,069: | ||
| | | | ||
| | | | ||
|- | |||
|- | |||
|Dx | |||
|Cystic Fibrosis | |||
|CFTR | |||
|University of Michigan, Hospital for Sick Children | |||
| | | | ||
|112 | |||
|non-exclusive | |||
|5776677 | |||
|5876974, 7118911, 6984487, 6730777, 5407796 | |||
| | | | ||
| | | | ||
|Johns Hopkins also has some key CFTR patents. | |||
| | | | ||
| | | | ||
Line 806: | Line 1,088: | ||
| | | | ||
| | | | ||
|- | |||
|- | |||
|Dx | |||
|Long-QT syndrome | |||
| | | | ||
|PGxHealth; Bio-Reference Laboratories | |||
| | | | ||
| | | | ||
Line 815: | Line 1,102: | ||
| | | | ||
| | | | ||
|[1], [2] | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|-- | |- | ||
|- | |||
|Dx | |||
|Spinocerebellar Ataxia | |||
| | | | ||
|Athena Diagnostics | |||
| | | | ||
| | | | ||
|exclusive | |||
| | | | ||
| | | | ||
| | | | ||
|Cook-Deegan notes “penumbra effect” wrt Athena | |||
| | | | ||
|[1], [2] | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|- | |||
|- | |||
|Dx | |||
|Tay-Sachs Disease | |||
| | | | ||
| | | | ||
Line 839: | Line 1,138: | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|[1], [2] | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|- | |||
|- | |||
|Dx | |||
|Canavan Disease | |||
| | | | ||
| | | | ||
Line 856: | Line 1,159: | ||
| | | | ||
| | | | ||
|[1], [2] | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|- | |||
|- | |||
|PGx | |||
|Coumadin (Warfarin) | |||
|CYP2C9 | |||
| | | | ||
| | | | ||
Line 867: | Line 1,175: | ||
| | | | ||
| | | | ||
|Nanosphere Verigene Warfarin Metabolism Nucleic Acid Test | |||
| | | | ||
| | | | ||
|[3] | |||
|http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108967.htm | |||
| | | | ||
| | | | ||
| | | | ||
|- | |||
|- | |||
|PGx | |||
|Coumadin (Warfarin) | |||
|VKORC1 | |||
| | | | ||
| | | | ||
Line 878: | Line 1,194: | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|[3] | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|- | |||
|- | |||
|PGx | |||
|Sprycel (dasatinib) | |||
|BCR-ABL | |||
| | | | ||
| | | | ||
Line 896: | Line 1,216: | ||
| | | | ||
| | | | ||
|[3] | |||
|http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=11215 | |||
| | | | ||
| | | | ||
| | | | ||
|---- | |---- | ||
| | |||
|} | |} | ||
Line 905: | Line 1,228: | ||
* used http://area23.brightbyte.de/csv2wp.php to convert CSV output from Numbers/Excel to wikimarkup | * used http://area23.brightbyte.de/csv2wp.php to convert CSV output from Numbers/Excel to wikimarkup | ||
* used http://simile.mit.edu/wiki/Wiki_Table_Editor to edit resulting table | * used http://simile.mit.edu/wiki/Wiki_Table_Editor to edit resulting table | ||
* [[Data,_narratives_and_tools_produced_by_the_Kits'_sector/GeneDxChart/CSV|also available as a CSV]] |
Latest revision as of 21:11, 13 November 2009
Type | disease / drug tested | genes | patent holder and/or exclusive licensees | Companies | Number of US labs offering testing | license | key patents | other patents | product | typical testing cost | notes | report | links | References | ||||||||||||||||||
Dx | Breast & Ovarian Cancer | BRCA1 | Myriad Genetics | Myriad Genetics | 1 | exclusive | 5753441, 6051379, | BRACAnalysis | $3120 [2] | [1], [2] | http://www.myriad.com/products/bracanalysis.php | [1] Cook-Deegan et al. The dangers of diagnostic monopolies. Nature (2009) vol. 458 (7237) pp. 405-6 | ||||||||||||||||||||
BRCA2 | [2] SACGHS. Appendix 1: Compendium of Case Studies on the Impact of Gene Patents and Licensing Practices on Access to Genetic Testing. (2009) pp. 1-305 | |||||||||||||||||||||||||||||||
Dx | colorectal cancer (HNPCC) | MLH1 | Oregon Health Sciences University + Dana Farber; Johns Hopkins | Baylor, Boston University, City of Hope, Harvard, Huntington, Mayo Clinic, University of Pennsylvania, Quest, Myriad, | ? | ? | 5922855, 5591826 (protein), 5693470 | ? | Myriad, MLH1 + MSH2 + MSH6: $2950; see [2] pg A-12 for more prices | Cho M et al. Effect of patents and licenses on the provision of clinical genetic testing services. Journal of Molecular Diagnostics 2003 (February). 5(1):3-8. NB: FAP and HNPCC “patent enforcements” are more unlikely given non-exclusive licensing and multiple rights-holders. | [1], [2] | [3] Flockhart et al. Clinically available pharmacogenomics tests. Clinical pharmacology and therapeutics (2009) vol. 86 (1) pp. 109-13 | ||||||||||||||||||||
MSH2 | ||||||||||||||||||||||||||||||||
MSH6 | ||||||||||||||||||||||||||||||||
Dx | colorectal cancer (FAP) | APC | ||||||||||||||||||||||||||||||
MYH | ||||||||||||||||||||||||||||||||
Dx | Alzheimer’s, late-onset (LOAD, AD2) | APOE | Duke university -> Athena Diagnostics (2 method patents for Dx alzheimer’s, don’t claim sequence, Bilski could destabilize; one claiming a kit) see [2]p B-6 | Athena (St Louis Health Science Center offers cheaper APOE Dx for cardivascular disease; SunnyBrook Molecular Genetics Laboratory & McGill University Health Center provide APOE testing for AD for ~$100 canadian, [2]B-8) | 1 | exclusive | 5508167, 5716828, 6027896 | ADmark® ApoE Genotype Analysis & Interpretation (Symptomatic) | $475 ($365 for cardiovascular sequencing by St Louis Health Science Center, see note) | Cook-Deegan notes “penumbra effect” wrt Athena. Athena sublicensed APOE for DTC testing to Smart Genetics, but First Inventor on patent raised licensing complaints for ethical reasons ([2] B-16). APOE also is a marker for cardiovascular disease; testing for which does not infringe the methods patents, see [2]B-8; http://snpedia.com/index.php/Alzheimer's_disease. Also 2 testing labs in Canada, McGill and Sunnybrook both offer APOE testing for AD for $100 & $120 respectively [2]B-8. | http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/qid/35 | |||||||||||||||||||||
Alzheimer’s, early-onset (EOAD, AD3) | PSEN1 | Hospital for Sick Children, U Toronto -> Athena | Athena | 1 | exclusive | 6194153 | 5986054, 6531586, 6248555(dropped), | ADmark® PS-1 DNA Sequencing Test | $1675 ([2]B-15) | http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/q/id/1261 | ||||||||||||||||||||||
Alzheimer’s, early-onset (EOAD, AD4) | PSEN2 | Hospital for Sick Children -> Athena | Athena | 1 | exclusive | 5840540 | 6485911 | ADmark® PS-2 DNA Sequencing Test | $1500?* | * http://www.alz.org/co/documents/2009_Symposium_handout_genetics.pdf | http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/q/id/1259 | |||||||||||||||||||||
Alzheimer’s, early-onset (EOAD, AD1) | APP | ? | Athena | 2 | ? | ? | ADmark® APP DNA Sequencing/Duplication Test; SignatureFISH | $1000?* | Signature genomics provides a FISH -based test for APP; only Athena does complete sequencing | http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/q/id/1260 http://www.signaturegenomics.com/signaturefish.html | ||||||||||||||||||||||
Dx | Haemochromatosis | HFE | Bio-Rad | mDx Hereditary Hemochromatosis ASR kit; mDx Hereditary Hemochromatosis LLA ASR | Merz JF, Kriss AG, Leonard DGB, Cho MK. Op. cit. Examine licensing activities around HFE and impact on diagnostic prices | |||||||||||||||||||||||||||
Dx | Cystic Fibrosis | CFTR | University of Michigan, Hospital for Sick Children | 112 | non-exclusive | 5776677 | 5876974, 7118911, 6984487, 6730777, 5407796 | Johns Hopkins also has some key CFTR patents. | ||||||||||||||||||||||||
Dx | Long-QT syndrome | PGxHealth; Bio-Reference Laboratories | [1], [2] | |||||||||||||||||||||||||||||
Dx | Spinocerebellar Ataxia | Athena Diagnostics | exclusive | Cook-Deegan notes “penumbra effect” wrt Athena | [1], [2] | |||||||||||||||||||||||||||
Dx | Tay-Sachs Disease | [1], [2] | ||||||||||||||||||||||||||||||
Dx | Canavan Disease | [1], [2] | ||||||||||||||||||||||||||||||
PGx | Coumadin (Warfarin) | CYP2C9 | Nanosphere Verigene Warfarin Metabolism Nucleic Acid Test | [3] | http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108967.htm | |||||||||||||||||||||||||||
PGx | Coumadin (Warfarin) | VKORC1 | [3] | |||||||||||||||||||||||||||||
PGx | Sprycel (dasatinib) | BCR-ABL | [3] | | | Type | disease / drug tested | genes | patent holder and/or exclusive licensees | Companies | Number of US labs offering testing | license | key patents | other patents | product | typical testing cost | notes | report | links | References | |||||||||||||
Dx | Breast & Ovarian Cancer | BRCA1 | Myriad Genetics | Myriad Genetics | 1 | exclusive | 5753441, 6051379, | BRACAnalysis | $3120 [2] | [1], [2] | http://www.myriad.com/products/bracanalysis.php | [1] Cook-Deegan et al. The dangers of diagnostic monopolies. Nature (2009) vol. 458 (7237) pp. 405-6 | ||||||||||||||||||||
BRCA2 | [2] SACGHS. Appendix 1: Compendium of Case Studies on the Impact of Gene Patents and Licensing Practices on Access to Genetic Testing. (2009) pp. 1-305 | |||||||||||||||||||||||||||||||
Dx | colorectal cancer (HNPCC) | MLH1 | Oregon Health Sciences University + Dana Farber; Johns Hopkins | Baylor, Boston University, City of Hope, Harvard, Huntington, Mayo Clinic, University of Pennsylvania, Quest, Myriad, | ? | ? | 5922855, 5591826 (protein), 5693470 | ? | Myriad, MLH1 + MSH2 + MSH6: $2950; see [2] pg A-12 for more prices | Cho M et al. Effect of patents and licenses on the provision of clinical genetic testing services. Journal of Molecular Diagnostics 2003 (February). 5(1):3-8. NB: FAP and HNPCC “patent enforcements” are more unlikely given non-exclusive licensing and multiple rights-holders. | [1], [2] | [3] Flockhart et al. Clinically available pharmacogenomics tests. Clinical pharmacology and therapeutics (2009) vol. 86 (1) pp. 109-13 | ||||||||||||||||||||
MSH2 | ||||||||||||||||||||||||||||||||
MSH6 | ||||||||||||||||||||||||||||||||
Dx | colorectal cancer (FAP) | APC | ||||||||||||||||||||||||||||||
MYH | ||||||||||||||||||||||||||||||||
Dx | Alzheimer’s, late-onset (LOAD, AD2) | APOE | Duke university -> Athena Diagnostics (2 method patents for Dx alzheimer’s, don’t claim sequence, Bilski could destabilize; one claiming a kit) see [2]p B-6 | Athena (St Louis Health Science Center offers cheaper APOE Dx for cardivascular disease; SunnyBrook Molecular Genetics Laboratory & McGill University Health Center provide APOE testing for AD for ~$100 canadian, [2]B-8) | 1 | exclusive | 5508167, 5716828, 6027896 | ADmark® ApoE Genotype Analysis & Interpretation (Symptomatic) | $475 ($365 for cardiovascular sequencing by St Louis Health Science Center, see note) | Cook-Deegan notes “penumbra effect” wrt Athena. Athena sublicensed APOE for DTC testing to Smart Genetics, but First Inventor on patent raised licensing complaints for ethical reasons ([2] B-16). APOE also is a marker for cardiovascular disease; testing for which does not infringe the methods patents, see [2]B-8; http://snpedia.com/index.php/Alzheimer's_disease. Also 2 testing labs in Canada, McGill and Sunnybrook both offer APOE testing for AD for $100 & $120 respectively [2]B-8. | http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/qid/35 | |||||||||||||||||||||
Alzheimer’s, early-onset (EOAD, AD3) | PSEN1 | Hospital for Sick Children, U Toronto -> Athena | Athena | 1 | exclusive | 6194153 | 5986054, 6531586, 6248555(dropped), | ADmark® PS-1 DNA Sequencing Test | $1675 ([2]B-15) | http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/q/id/1261 | ||||||||||||||||||||||
Alzheimer’s, early-onset (EOAD, AD4) | PSEN2 | Hospital for Sick Children -> Athena | Athena | 1 | exclusive | 5840540 | 6485911 | ADmark® PS-2 DNA Sequencing Test | $1500?* | * http://www.alz.org/co/documents/2009_Symposium_handout_genetics.pdf | http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/q/id/1259 | |||||||||||||||||||||
Alzheimer’s, early-onset (EOAD, AD1) | APP | ? | Athena | 2 | ? | ? | ADmark® APP DNA Sequencing/Duplication Test; SignatureFISH | $1000?* | Signature genomics provides a FISH -based test for APP; only Athena does complete sequencing | http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/q/id/1260 http://www.signaturegenomics.com/signaturefish.html | ||||||||||||||||||||||
Dx | Haemochromatosis | HFE | Bio-Rad | mDx Hereditary Hemochromatosis ASR kit; mDx Hereditary Hemochromatosis LLA ASR | Merz JF, Kriss AG, Leonard DGB, Cho MK. Op. cit. Examine licensing activities around HFE and impact on diagnostic prices | |||||||||||||||||||||||||||
Dx | Cystic Fibrosis | CFTR | University of Michigan, Hospital for Sick Children | 112 | non-exclusive | 5776677 | 5876974, 7118911, 6984487, 6730777, 5407796 | Johns Hopkins also has some key CFTR patents. | ||||||||||||||||||||||||
Dx | Long-QT syndrome | PGxHealth; Bio-Reference Laboratories | [1], [2] | |||||||||||||||||||||||||||||
Dx | Spinocerebellar Ataxia | Athena Diagnostics | exclusive | Cook-Deegan notes “penumbra effect” wrt Athena | [1], [2] | |||||||||||||||||||||||||||
Dx | Tay-Sachs Disease | [1], [2] | ||||||||||||||||||||||||||||||
Dx | Canavan Disease | [1], [2] | ||||||||||||||||||||||||||||||
PGx | Coumadin (Warfarin) | CYP2C9 | Nanosphere Verigene Warfarin Metabolism Nucleic Acid Test | [3] | http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108967.htm | |||||||||||||||||||||||||||
PGx | Coumadin (Warfarin) | VKORC1 | [3] | |||||||||||||||||||||||||||||
PGx | Sprycel (dasatinib) | BCR-ABL | [3] | -ype | disease / drug tested | genes | patent holder and/or exclusive licensees | Companies | Number of US labs offering testing | license | key patents | other patents | product | typical testing cost | notes | report | links | References | ||||||||||||||
Dx | Breast & Ovarian Cancer | BRCA1 | Myriad Genetics | Myriad Genetics | 1 | exclusive | 5753441, 6051379, | BRACAnalysis | $3120 [2] | [1], [2] | http://www.myriad.com/products/bracanalysis.php | [1] Cook-Deegan et al. The dangers of diagnostic monopolies. Nature (2009) vol. 458 (7237) pp. 405-6 | ||||||||||||||||||||
BRCA2 | [2] SACGHS. Appendix 1: Compendium of Case Studies on the Impact of Gene Patents and Licensing Practices on Access to Genetic Testing. (2009) pp. 1-305 | |||||||||||||||||||||||||||||||
Dx | colorectal cancer (HNPCC) | MLH1 | Oregon Health Sciences University + Dana Farber; Johns Hopkins | Baylor, Boston University, City of Hope, Harvard, Huntington, Mayo Clinic, University of Pennsylvania, Quest, Myriad, | ? | ? | 5922855, 5591826 (protein), 5693470 | ? | Myriad, MLH1 + MSH2 + MSH6: $2950; see [2] pg A-12 for more prices | Cho M et al. Effect of patents and licenses on the provision of clinical genetic testing services. Journal of Molecular Diagnostics 2003 (February). 5(1):3-8. NB: FAP and HNPCC “patent enforcements” are more unlikely given non-exclusive licensing and multiple rights-holders. | [1], [2] | [3] Flockhart et al. Clinically available pharmacogenomics tests. Clinical pharmacology and therapeutics (2009) vol. 86 (1) pp. 109-13 | ||||||||||||||||||||
MSH2 | ||||||||||||||||||||||||||||||||
MSH6 | ||||||||||||||||||||||||||||||||
Dx | colorectal cancer (FAP) | APC | ||||||||||||||||||||||||||||||
MYH | ||||||||||||||||||||||||||||||||
Dx | Alzheimer’s, late-onset (LOAD, AD2) | APOE | Duke university -> Athena Diagnostics (2 method patents for Dx alzheimer’s, don’t claim sequence, Bilski could destabilize; one claiming a kit) see [2]p B-6 | Athena (St Louis Health Science Center offers cheaper APOE Dx for cardivascular disease; SunnyBrook Molecular Genetics Laboratory & McGill University Health Center provide APOE testing for AD for ~$100 canadian, [2]B-8) | 1 | exclusive | 5508167, 5716828, 6027896 | ADmark® ApoE Genotype Analysis & Interpretation (Symptomatic) | $475 ($365 for cardiovascular sequencing by St Louis Health Science Center, see note) | Cook-Deegan notes “penumbra effect” wrt Athena. Athena sublicensed APOE for DTC testing to Smart Genetics, but First Inventor on patent raised licensing complaints for ethical reasons ([2] B-16). APOE also is a marker for cardiovascular disease; testing for which does not infringe the methods patents, see [2]B-8; http://snpedia.com/index.php/Alzheimer's_disease. Also 2 testing labs in Canada, McGill and Sunnybrook both offer APOE testing for AD for $100 & $120 respectively [2]B-8. | http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/qid/35 | |||||||||||||||||||||
Alzheimer’s, early-onset (EOAD, AD3) | PSEN1 | Hospital for Sick Children, U Toronto -> Athena | Athena | 1 | exclusive | 6194153 | 5986054, 6531586, 6248555(dropped), | ADmark® PS-1 DNA Sequencing Test | $1675 ([2]B-15) | http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/q/id/1261 | ||||||||||||||||||||||
Alzheimer’s, early-onset (EOAD, AD4) | PSEN2 | Hospital for Sick Children -> Athena | Athena | 1 | exclusive | 5840540 | 6485911 | ADmark® PS-2 DNA Sequencing Test | $1500?* | * http://www.alz.org/co/documents/2009_Symposium_handout_genetics.pdf | http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/q/id/1259 | |||||||||||||||||||||
Alzheimer’s, early-onset (EOAD, AD1) | APP | ? | Athena | 2 | ? | ? | ADmark® APP DNA Sequencing/Duplication Test; SignatureFISH | $1000?* | Signature genomics provides a FISH -based test for APP; only Athena does complete sequencing | http://www.athenadiagnostics.com/content/test-catalog/find-test/service-detail/q/id/1260 http://www.signaturegenomics.com/signaturefish.html | ||||||||||||||||||||||
Dx | Haemochromatosis | HFE | Bio-Rad | mDx Hereditary Hemochromatosis ASR kit; mDx Hereditary Hemochromatosis LLA ASR | Merz JF, Kriss AG, Leonard DGB, Cho MK. Op. cit. Examine licensing activities around HFE and impact on diagnostic prices | |||||||||||||||||||||||||||
Dx | Cystic Fibrosis | CFTR | University of Michigan, Hospital for Sick Children | 112 | non-exclusive | 5776677 | 5876974, 7118911, 6984487, 6730777, 5407796 | Johns Hopkins also has some key CFTR patents. | ||||||||||||||||||||||||
Dx | Long-QT syndrome | PGxHealth; Bio-Reference Laboratories | [1], [2] | |||||||||||||||||||||||||||||
Dx | Spinocerebellar Ataxia | Athena Diagnostics | exclusive | Cook-Deegan notes “penumbra effect” wrt Athena | [1], [2] | |||||||||||||||||||||||||||
Dx | Tay-Sachs Disease | [1], [2] | ||||||||||||||||||||||||||||||
Dx | Canavan Disease | [1], [2] | ||||||||||||||||||||||||||||||
PGx | Coumadin (Warfarin) | CYP2C9 | Nanosphere Verigene Warfarin Metabolism Nucleic Acid Test | [3] | http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108967.htm | |||||||||||||||||||||||||||
PGx | Coumadin (Warfarin) | VKORC1 | [3] | |||||||||||||||||||||||||||||
PGx | Sprycel (dasatinib) | BCR-ABL | [3] | http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=11215 | ||||||||||||||||||||||||||||
Notes:
- used http://area23.brightbyte.de/csv2wp.php to convert CSV output from Numbers/Excel to wikimarkup
- used http://simile.mit.edu/wiki/Wiki_Table_Editor to edit resulting table
- also available as a CSV